Levi Strauss & Co. vs Sanofi SA — how do they compare? Levi Strauss & Co. trades at $22.7 (market cap $9.09B), while Sanofi SA trades at $43.52 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 11.5× Levi Strauss & Co.'s market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| LEVI | SNY | |
|---|---|---|
Market Cap | $9.09B | $104.57B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $52.34 |
52-Week Low | $17.92 | $41.33 |
Enterprise Value | $10.40B | $124.48B |
Dividend Yield | 2.71% | 5.56% |
Trailing returns across standard periods
Latest headlines on both assets
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →